Magnetic properties of hydrothermally synthesized greigite (Fe3S4)- II. High- and low-temperature characteristics

The magnetic behaviour of hydrothermally synthesized greigite was analysed in the temperature range from 4 K to 700 °C. Below room temperature, hysteresis parameters were determined as a function of temperature, with emphasis on the temperature range below 50 K. Saturation magnetization and initial susceptibility were studied above room temperature, along with X-ray diVraction analysis of material heated to various temperatures. The magnetic behaviour of synthetic greigite on heating is determined by chemical alteration rather than by magnetic unblocking. Heating in air yields more discriminative behaviour than heating in argon. When heated in air, the amount of oxygen available for reaction with greigite determines the products and magnetic behaviour. In systems open to contact with air, haematite is the final reaction product. When the contact with air is restricted, magnetite is the final reaction product. When air is excluded, pyrrhotite and magnetite are the final reaction products; the amount of magnetite formed is determined by the purity of the starting greigite and the degree of its surficial oxidation. The saturation magnetization of synthetic greigite is virtually independent of temperature from room temperature down to 4 K. The saturation remanent magnetization increases slowly by 20-30 per cent on cooling from room temperature to 4 K. A broad maximum is observed at ~10 K which may be diagnostic of greigite. The coercive and remanent coercive force both increase smoothly with decreasing temperature to 4 K. The coercive force increases from ~50 mT at room temperature to approximately 100-120 mT at 4 K, and the remanent coercive force increases from approximately 50-80 mT at room temperature to approximately 110-180 mT at 4 K

Magnetic properties and geochemistry of the active oxidation front and the youngest sapropel in the eastern Mediterranean Sea

Magnetic properties (IRM, ARM, xin, S-ratio at 0.3 T, room temperature (RT) hysteresis and thermomagnetic curves) and geochemical data (Fe, S, Mn, Al, Ti, organic C) were studied in two eastern Mediterranean boxcores (ABC26 and BC19) at a resolution of 3-5 mm. The boxcores contain sapropel S1 (9-6 kyr BP) at a few decimetres below seafloor. The magnetic fraction consists predominantly of single-domain (SD) to pseudo-singledomain (PSD) magnetite in the entire cores. The original input of magnetic grains comes from two sources: aeolian dust (both cores) and volcanic ash from the Minoan eruption of Santorini (core BC19 only). Non-steady-state diagenesis has changed the magnetic mineralogy considerably in these alternating organic-rich/organic-poor sediments. During deposition of sapropel S1, reductive diagenesis and pyritization in and just below the sapropel caused lower magnetic intensities, coarser magnetic grain sizes and partial maghemitization. In thermomagnetic curves two types of pyrite can be identified: one oxidizes below 450 uC and the other above 450 uC. The higher oxidation temperature is predominantly found below the sapropel. This may be related to the microtexture of pyrite, which is euhedral below sapropels and mainly framboidal within sapropels. Since the end of sapropel deposition a downward moving oxidation front has oxidized the upper half (c. 5 cm) of the sapropel. The oxidized part of the sapropel is enriched in diagenetically formed Fe oxides with relatively high coercivity and ARM. The maximum coercivity is found in a distinct layer between the present-day Mn- and Fe-redox boundaries at the top of the unoxidized sapropel. The freshly precipitated Fe oxides in this centimetre-thick layer contain a mixture of superparamagnetic (SP) grains and high-coercivity SD magnetite. Higher in the oxidized zone the freshly precipitated Fe oxides have aged into generally slightly lower-coercivity SD grains, with relatively high ARM. In addition to the diagenetic formation of Fe oxides at the top of the sapropel, formation of a ferrimagnetic Fe monosulphide may have occurred within the sapropel during later stages of diagenesis, which may have enhanced the ARM signal in the organic-rich interval in particular

Medication use in pregnancy: a cross-sectional, multinational web-based study

Objectives: Intercountry comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. his study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilised and indication for use. Design: Cross-sectional, web-based study performed within the period from 1 October 2011 to 29 February 2012. Uniform collection of drug utilisation data was performed via an anonymous online questionnaire. Setting: Multinational study in Europe (Western, Northern and Eastern), North and South America and Australia. Participants: Pregnant women and new mothers with children less than 1 year of age. Primary and secondary outcome measures: Prevalence of and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use. Results: The study population included 9459 women, of which 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17% of women reported use of at least one medication for treatment of ute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (adjusted OR (aOR): 0.55, 95% CI 0.34 to 0.87) and Northern Europe (aOR: 0.50, 95% CI 0.31 to 0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than nonimmigrants. Conclusions: In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used

Notes on Modeling XML Content Models

We describe a method for modeling element content of XML-elements. Often, these models are simple, but complex ones occur. Because modeling the complex ones is not trivial, designers of these models may have problems with drawing up correct and concise models. As far as we know, study books about XML do not present methods for this type of modeling. The method we propose is based on modeling regular expressions. Using this, it is possible to model element content of XML-elements more systematically

Organs-on-Chips in Drug Development: The Importance of Involving Stakeholders in Early Health Technology Assessment

Organs-on-chips are three-dimensional, microfluidic cell culture systems that simulate the function of tissues and organ subunits. Organ-on-chip systems are expected to contribute to drug candidate screening and the reduction of animal tests in preclinical drug development and may increase efficiency of these processes. To maximize the future impact of the technology on drug development, it is important to make informed decisions regarding the attributes and features of organs-on-chips even though the technology is still in a stage of early development. It is likely that different stakeholders in organ-on-chip development, such as engineers, biologists, regulatory scientists, and pharmaceutical researchers, will have different perspectives on how to maximize the future impact of the technology. Various aspects of organ-on-chip development, such as cost, materials, features, cell source, read-out technology, types of data, and compatibility with existing technology, will likely be judged differently by different stakeholders. Early health technology assessment (HTA) is needed in order to facilitate the essential integration of such potentially conflicting views in the process of technology development. In this critical review we discuss the potential impact of organs-on-chips on the drug development process, and we use a pilot study to give examples of how different stakeholders have different perspectives on attributes of organ-on-chip technology. As a future tool in early HTA of organs-on-chips, we suggest the use of multicriteria decision analysis (MCDA), which is a formal method to deal with multiple and conflicting criteria in technology development. We argue that it is essential to design and perform a comprehensive MCDA for organ-on-chip development, and so the future impact of this technology in the pharmaceutical industry can be maximized

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

Drugs targeting atrial-specific ion channels, K(v)1.5 or K(ir)3.1/3.4, are being developed as new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried out in non-cardiac cell lines or animal models may not accurately represent the physiology of a human cardiomyocyte (CM). In the current study, we tested whether human embryonic stem cell (hESC)-derived atrial CMs could predict atrial selectivity of pharmacological compounds. By modulating retinoic acid signaling during hESC differentiation, we generated atrial-like (hESC-atrial) and ventricular-like (hESC-ventricular) CMs. We found the expression of atrial-specific ion channel genes, KCNA5 (encoding Kv1.5) and KCNJ3 (encoding K-ir 3.1), in hESC-atrial CMs and further demonstrated that these ion channel genes are regulated by COUP-TF transcription factors. Moreover, in response to multiple ion channel blocker, vernakalant, and K(v)1.5 blocker, XEN-D0101, hESC-atrial but not hESC-ventricular CMs showed action potential (AP) prolongation due to a reduction in early repolarization. In hESC-atrial CMs, XEN-R0703, a novel K(ir)3.1/3.4 blocker restored the AP shortening caused by CCh. Neither CCh nor XEN-R0703 had an effect on hESC-ventricular CMs. In summary, we demonstrate that hESC-atrial CMs are a robust model for pre-clinical testing to assess atrial selectivity of novel antiarrhythmic drugs